| Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets, which are approved for renal cell carcinoma and previously treated hepatocellular carcinoma; COMETRIQ® (cabozantinib) capsules, which are approved for progressive, metastatic medullary thyroid cancer; COTELLIC® (cobimetinib), which is an inhibitor of MEK approved as part of a combination regimen to treat melanoma; and MINNEBRO® (esaxerenone), which is an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension. We show 47 historical shares outstanding datapoints in our coverage of EXEL's shares outstanding history.|
Understanding the changing numbers of EXEL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like EXEL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching EXEL by allowing them to research EXEL shares outstanding history
as well as any other stock in our coverage universe.